Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas.
Pancreas · 2017
Last updated 2026-05-28In a study on rats, 10 weeks of exenatide injections caused damage to the pancreas, including changes in cell structure. The treatment also increased levels of certain proteins linked to cell stress and cell death in both rat pancreas tissue and cultured pancreatic cells.
AI summary of the abstract below.
| Journal | Pancreas, 2017 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.08 |
| NIH percentile | 6 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
OBJECTIVES: The study aimed to explore the alteration of autophagy in rat pancreas treated with exenatide.
METHODS: Normal Sprague-Dawley rats and diabetes-model rats induced by 2-month high-sugar and high-fat diet and streptozotocin injection were subcutaneously injected with exenatide, respectively, for 10 weeks, with homologous rats treated with saline as control. Meanwhile, AR42J cells, pancreatic acinar cell line, were cultured with exenatide at doses of 5 pM for 3 days. The pancreas was disposed, and several sections were stained with hematoxylin-eosin. Immunohistochemistry was used to measure the expressions of glucagon-like peptide 1 receptor (GLP-1R) and cysteine-aspartic acid protease-3 in rat pancreas, and Western blot was used to test the expressions of GLP-1R, light chain 3B-I and -II, and p62 in rat pancreas and AR42J cells. The data were expressed as mean (standard deviation) and analyzed by unpaired Student's t-test.
RESULTS: Exenatide can induce pathological changes in rat pancreas. The GLP-1R, p62, light chain 3B-II, and cysteine-aspartic acid protease-3 in rat pancreas and AR42J cells treated with exenatide were significantly overexpressed.
CONCLUSIONS: Exenatide can activate and upregulate its receptor, GLP-1R, then impair autophagy flux and activate apoptosis in the pancreatic acinar cell, thus damaging rat pancreas.
Verbatim abstract via PubMed 27518464 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.